Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

Molecular Metabolism

Volumn 6, Issue 5, 2017, Pages 440-446

  Jall, Sigrid ^a,b   Sachs, Stephan ^a,e   Clemmensen, Christoffer ^a,b,c   Finan, Brian ^a,b,c   Neff, Frauke ^a   DiMarchi, Richard D ^d   Tschöp, Matthias H ^a,b,c   Müller, Timo D ^a,b,c   Hofmann, Susanna M ^a,c,e  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d INDIANA UNIVERSITY   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Diabetes; Dyslipidemia; Glucose homeostasis; Obesity; Pharmacotherapy; Sex differences

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DYSLIPIDEMIA; FAT MASS; FATTY LIVER; FEMALE; FOOD INTAKE; GLUCOSE METABOLISM; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; SEX DIFFERENCE; SUGAR INTAKE; ANIMAL; C57BL MOUSE; EATING; METABOLISM; SEX FACTOR;

ADIPOSITY; ANIMALS; DIET, HIGH-FAT; DYSLIPIDEMIAS; EATING; FATTY LIVER; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; MALE; MICE; MICE, INBRED C57BL; OBESITY; SEX FACTORS;

EID: 85014827561     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2017.02.002     Document Type: Article

References (33)

1. [1] Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
2. [2] Dee, A., Kearns, K., O'Neill, C., Sharp, L., Staines, A., O'Dwyer, V., et al. The direct and indirect costs of both overweight and obesity: a systematic review. BMC Research Notes, 7, 2014, 242.
3. [3] Tuomilehto, J., Lindstrom, J., Eriksson, J.G., Valle, T.T., Hamalainen, H., Ilanne-Parikka, P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine 344 (2001), 1343–1350.
4. [4] Wadden, T.A., Berkowitz, R.I., Womble, L.G., Sarwer, D.B., Phelan, S., Cato, R.K., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. The New England Journal of Medicine 353 (2005), 2111–2120.
5. [5] Krentz, A.J., Fujioka, K., Hompesch, M., Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes, Obesity and Metabolism 18 (2016), 558–570.
6. [6] Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Brethauer, S.A., Navaneethan, S.D., et al. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. The New England Journal of Medicine 370 (2014), 2002–2013.
7. [7] Hoerger, T.J., Zhang, P., Segel, J.E., Kahn, H.S., Barker, L.E., Couper, S., Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 33 (2010), 1933–1939.
8. [8] Fuchs, H.F., Broderick, R.C., Harnsberger, C.R., Chang, D.C., Sandler, B.J., Jacobsen, G.R., et al. Benefits of bariatric surgery do not reach obese men. Journal of Laparoendoscopic & Advanced Surgical Techniques Part A 25 (2015), 196–201.
9. [9] Nguyen, D.M., El-Serag, H.B., The epidemiology of obesity. Gastroenterology Clinics of North America 39 (2010), 1–7.
10. [10] Pettersson, U.S., Walden, T.B., Carlsson, P.O., Jansson, L., Phillipson, M., Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue. PLoS One, 7, 2012, e46057.
11. [11] Hong, J., Stubbins, R.E., Smith, R.R., Harvey, A.E., Nunez, N.P., Differential susceptibility to obesity between male, female and ovariectomized female mice. Nutrition Journal, 8, 2009, 11.
12. [12] Wizemann, T.M., Pardue, M.L., Exploring the biological contributions to human health: does sex matter?. 2001, National Academies Press, Washington (DC).
13. [13] Shi, H., Clegg, D.J., Sex differences in the regulation of body weight. Physiology& Behavior 97 (2009), 199–204.
14. [14] Franconi, F., Brunelleschi, S., Steardo, L., Cuomo, V., Gender differences in drug responses. Pharmacological Research 55 (2007), 81–95.
15. [15] Martin, R.M., Biswas, P.N., Freemantle, S.N., Pearce, G.L., Mann, R.D., Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. British Journal of Clinical Pharmacology 46 (1998), 505–511.
16. [16] Clayton, J.A., Collins, F.S., Policy: NIH to balance sex in cell and animal studies. Nature 509 (2014), 282–283.
17. [17] Tschöp, M.H., DiMarchi, R.D., Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies. Diabetes 61 (2012), 1309–1314.
18. [18] Tschöp, M.H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T.D., et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metabolism 24 (2016), 51–62.
19. [19] Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine 21 (2015), 27–36.
20. [20] Yang, Y., Smith, D.L. Jr., Keating, K.D., Allison, D.B., Nagy, T.R., Variations in body weight, food intake and body composition after long-term high-fat diet feeding in C57BL/6J mice. Obesity (Silver Spring) 22 (2014), 2147–2155.
21. [21] National Institutes of Health, National research council (US) committee for the update of the Guide for the Care and use of laboratory Animals. Guide for the Care and use of laboratory Animals. 2011, 10.17226/12910 Available from: https://www.ncbi.nlm.nih.gov/books/NBK54050/ Accessed 23 January 2017.
22. [22] Clemmensen, C., Chabenne, J., Finan, B., Sullivan, L., Fischer, K., Kuchler, D., et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63 (2014), 1422–1427.
23. [23] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
24. [24] Hofmann, S.M., Perez-Tilve, D., Greer, T.M., Coburn, B.A., Grant, E., Basford, J.E., et al. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 57 (2008), 5–12.
25. [25] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
26. [26] Morselli, E., Fuente-Martin, E., Finan, B., Kim, M., Frank, A., Garcia-Caceres, C., et al. Hypothalamic PGC-1alpha protects against high-fat diet exposure by regulating ERalpha. Cell Reports 9 (2014), 633–645.
27. [27] Lundgren, H., Bengtsson, C., Blohme, G., Lapidus, L., Waldenstrom, J., Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabetic Medicine 7 (1990), 407–413.
28. [28] Spruss, A., Henkel, J., Kanuri, G., Blank, D., Puschel, G.P., Bischoff, S.C., et al. Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Molecular Medicine 18 (2012), 1346–1355.
29. [29] Ganz, M., Csak, T., Szabo, G., High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World Journal of Gastroenterology 20 (2014), 8525–8534.
30. [30] Ni, Y., Nagashimada, M., Zhuge, F., Zhan, L., Nagata, N., Tsutsui, A., et al. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: a comparison with vitamin E. Scientific Reports, 5, 2015, 17192.
31. [31] Giannini, E.G., Testa, R., Savarino, V., Liver enzyme alteration: a guide for clinicians. CMAJ 172 (2005), 367–379.
32. [32] Yin, D.P., Gao, Q., Ma, L.L., Yan, W., Williams, P.E., McGuinness, O.P., et al. Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice. Annals of Surgery 254 (2011), 73–82.
33. [33] Frank, A.P., Zechner, J.F., Clegg, D.J., Gastric bypass surgery but not caloric restriction improves reproductive function in obese mice. Obesity Surgery 26 (2016), 467–473.